Bulletin from the Annual General Meeting on 11 June 2024 in Diagonal Bio AB
Resolution on adoption of the accounts and appropriation of profit
The Annual General Meeting resolved to adopt the income statement and the balance sheet. The Annual General Meeting also resolved to dispose of the company’s profit in accordance with the board’s proposal, meaning that no dividend will be paid and that available funds will be carried forward.
Discharge from liability for the members of the board of the directors and the CEO
The Annual General Meeting resolved to discharge the members of the board and the CEO from liability for the financial year 2023.
Election and remuneration of the board of directors and auditor
The Annual General Meeting resolved, in accordance with the nomination committee’s proposal, to re-elect Kerstin Jakobsson, Edvard Hall and Kushagr Punyani as members of the board, and to re-elect Kerstin Jakobsson as chairman of the board. The previous board member Karin Wehlin had declined re-election.
The Annual General Meeting further resolved, in accordance with the nomination committee’s proposal, that remuneration shall be paid with five price base amounts to the chairman of the board and with two price base amounts to each ordinary board member. Fees to the auditor shall be paid according to an approved invoice in accordance with customary billing standards.
The Annual General Meeting finally resolved, in accordance with the nomination committee’s proposal, to re-elect Mazars AB as auditor. Mazars AB has announced that authorized public accountant Jesper Ahlkvist will continue to be the auditor in charge.
Resolution on authorizing the board of directors to issue new shares
The Annual General Meeting resolved, in accordance with the board’s proposal, to authorize the board, on one or more occasions, to decide on the issuance of shares, warrants, and/or convertibles. The authorization is limited so that the number of shares, after full subscription of new issues, full utilization of warrants, or full conversion, does not increase by more than twenty (20) percent of the number of shares outstanding at the time of this meeting. The authorization shall be valid until the next annual general meeting. Issuances can be made with or without deviation from the shareholders’ preferential rights and shall be made at a subscription price assessed by the board to be marketbased, subject to customary issue discounts where applicable. The board shall have the right to decide on the detailed terms of each issue. In addition to cash payment, payment may also be made with in-kind contributions or through set-off, or otherwise under certain conditions.
Resolution regarding the principles for the appointment of the nomination committee and instructions for the nomination committee’s work
The Annual General Meeting resolved, in accordance with the nomination committee’s proposal, not to change the procedures and instructions for the nomination committee.
Lund, 11 June 2024
Diagonal Bio AB (publ)
This information was submitted for publication, through the agency of the contact person set out below, at 15:00 CEST on 11 June 2024.
For additional information about Diagonal Bio AB
Please contact: Karin Wehlin, CEO
Phone: +46 703 052 488
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionizing global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio’s patented technology can also be used for the less regulated market segments via LAMPlify®.
